TD Cowen started coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Free Report) in a research note issued to investors on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $15.00 target price on the stock.
Other analysts have also issued research reports about the stock. Barclays started coverage on shares of Anteris Technologies Global in a research report on Tuesday. They set an “overweight” rating and a $22.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Anteris Technologies Global in a research note on Tuesday. They issued an “overweight” rating and a $9.00 price objective for the company.
Check Out Our Latest Report on Anteris Technologies Global
Anteris Technologies Global Trading Down 2.1 %
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Featured Articles
- Five stocks we like better than Anteris Technologies Global
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- ETF Screener: Uses and Step-by-Step Guide
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- How to Calculate Stock Profit
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
